ImmunityBio (IBRX) News Today $3.23 -0.09 (-2.71%) (As of 10/10/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period ImmunityBio (NASDAQ:IBRX) Trading Down 4.5% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.5% - Here's WhyOctober 9 at 1:50 PM | marketbeat.comImmunityBio: Moving The NeedleOctober 7 at 4:34 PM | seekingalpha.comMore layoffs for ImmunityBio's Dunkirk facilityOctober 2, 2024 | bizjournals.comBluebird Bio To Reduce Approx. 25% Of Its Workforce - Quick FactsSeptember 24, 2024 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) Trading Down 3.2%ImmunityBio (NASDAQ:IBRX) Stock Price Down 3.2%September 17, 2024 | marketbeat.comBank of New York Mellon Corp Has $3.93 Million Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)Bank of New York Mellon Corp boosted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 37.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 621,536 shares of the company's stockSeptember 15, 2024 | marketbeat.comImmunitybio Inc. (IBRX): Fast-Growing Penny Stock To ConsiderSeptember 12, 2024 | msn.comImmunityBio reports extended survival in NSCLC therapy trialSeptember 11, 2024 | uk.investing.comImmunityBio (NASDAQ:IBRX) Stock Price Up 6.8%ImmunityBio (NASDAQ:IBRX) Trading 6.8% HigherSeptember 9, 2024 | marketbeat.comShort Interest in ImmunityBio, Inc. (NASDAQ:IBRX) Grows By 5.2%ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 49,180,000 shares, a growth of 5.2% from the July 31st total of 46,770,000 shares. Based on an average daily volume of 3,240,000 shares, the short-interest ratio is currently 15.2 days. Approximately 31.6% of the company's shares are short sold.September 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 3.7%ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7%August 30, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 7.8%ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.8%August 21, 2024 | marketbeat.comPiper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)August 19, 2024 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) PT Lowered to $4.75 at Piper SandlerPiper Sandler lowered their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a report on Monday.August 19, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6% ImmunityBio (NASDAQ:IBRX) Trading Down 6%August 19, 2024 | marketbeat.comImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me CautiousAugust 19, 2024 | seekingalpha.comABSI Sep 2024 6.000 callAugust 13, 2024 | ca.finance.yahoo.comCompany News for Aug 13, 2024August 13, 2024 | msn.comImmunityBio (NASDAQ:IBRX) Shares Down 2.7% After Earnings MissImmunityBio (NASDAQ:IBRX) Shares Down 2.7% on Disappointing EarningsAugust 13, 2024 | marketbeat.comImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalAugust 12, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Up 6.9%ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.9%August 9, 2024 | marketbeat.comImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerAugust 6, 2024 | finance.yahoo.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,539,590 shares of the company's stock after purchasingAugust 6, 2024 | marketbeat.comIBRX Aug 2024 4.000 put (IBRX240809P00004000)August 5, 2024 | finance.yahoo.comIBRX Aug 2024 6.500 call (IBRX240809C00006500)August 5, 2024 | finance.yahoo.comKuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmJuly 25, 2024 | prnewswire.comHealthcare Services Group is about to announce its earnings — here's what to expectJuly 23, 2024 | markets.businessinsider.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 23, 2024 | investorplace.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Blair William & Co. ILBlair William & Co. IL raised its stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 106.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 313,542 shares of the company's stock after buying an additional 161,530 shares durJuly 22, 2024 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Down 8.2% in JuneImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 49,080,000 shares, a drop of 8.2% from the June 15th total of 53,440,000 shares. Approximately 31.8% of the shares of the company are short sold. Based on an average daily trading volume, of 6,770,000 shares, the short-interest ratio is presently 7.2 days.July 16, 2024 | marketbeat.comImmunityBio: All Eyes On Execution Now (Rating Upgrade)July 8, 2024 | seekingalpha.comImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze PotentialJune 25, 2024 | seekingalpha.comImmunityBio (NASDAQ:IBRX) Shares Down 3.7% ImmunityBio (NASDAQ:IBRX) Shares Down 3.7%June 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up to $6.23ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $6.23June 20, 2024 | marketbeat.com3 Short-Squeeze Stocks Outwitting the Pessimistic PredictionsJune 20, 2024 | investorplace.comImmunityBio (NASDAQ:IBRX) Trading 5.1% Higher ImmunityBio (NASDAQ:IBRX) Stock Price Up 5.1%June 18, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 3.9%ImmunityBio (NASDAQ:IBRX) Trading Down 3.9%June 12, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 2.9%ImmunityBio (NASDAQ:IBRX) Trading Up 2.9%June 11, 2024 | marketbeat.com739,808 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Rafferty Asset Management LLCRafferty Asset Management LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 739,808 shares of the coJune 8, 2024 | marketbeat.comImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateJune 7, 2024 | businesswire.comImmunityBio: Anktiva's Launch Demands A ReassessmentJune 6, 2024 | seekingalpha.comImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.36ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.36June 6, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 3.3%ImmunityBio (NASDAQ:IBRX) Trading Down 3.3%June 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 4.4%ImmunityBio (NASDAQ:IBRX) Trading Up 4.4%May 31, 2024 | marketbeat.comWhat the Options Market Tells Us About ImmunityBioMay 17, 2024 | benzinga.comConnecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastMay 17, 2024 | businesswire.comImmunityBio (NASDAQ:IBRX) Shares Down 4.2% ImmunityBio (NASDAQ:IBRX) Shares Down 4.2%May 16, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 8.9%ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9%May 13, 2024 | marketbeat.comImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 11, 2024 | finance.yahoo.comIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024May 10, 2024 | investorplace.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address No matter the outcome of the election, it could be a death sentence for your wealth... (Ad)In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional investment options. So, Why Gold? Why Now? IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.750.72▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼42▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VCYT News HRMY News BCRX News SANA News FLGT News EBS News ALEC News TSHA News SAGE News ITOS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 10/10/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the n...InvestorPlace | SponsoredAI Expert Reveals New PickWhy You Shouldn't Pour All Your Money Into Nvidia Jeff Brown, who predicted Nvidia's rise, warns against pu...Brownstone Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
